US-based medical technology company Establishment Labs Holdings Inc., (NASDAQ: ESTA) has announced that it has received product approval from China’s National Medical Products Administration (NMPA) for its Motiva silicone gel-filled breast implants. This marks the company’s first approval in China, the world’s second-largest market for breast implants. Originally approved in South Korea in 2016, the NMPA’s approval precedes that of the US market, where Motiva implants are still under clinical development. Establishment Labs is committed to enhancing women’s health and provides a comprehensive portfolio of solutions for breast health, aesthetics, and reconstruction.
Expanding Global Reach and Impact on Women’s Health
Establishment Labs’ receipt of NMPA approval for Motiva implants signifies a significant step in expanding its global reach. The company’s dedication to improving women’s health is evident through its broad offering of products and services that cater to the diverse needs of breast health, aesthetics, and reconstruction.- Flcube.com
